PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2390/2/11 Alcon Laboratories

AUTH/2390/2/11: Anonymous representative v Alcon β€” Azarga pH demonstration (No breach)

Anonymous complaint alleged reps used litmus paper and eye drops to demonstrate pH and encouraged instillation into eyes. Panel found no evidence…

2018
CASE
AUTH/3093/9/18 Roche Products

AUTH/3093/9/18: Director v Roche β€” Clinical trial disclosure (No breach)

BMJ analysis suggested Roche had 15 due EUCTR trials without posted results. Panel found 14 had no UK nexus and 1 UK-site…

2011
CASE
AUTH/2403/5/11 Boehringer Ingelheim

Boehringer Ingelheim press release on Pradaxa: ruled unbalanced for omitting bleeding risk (AUTH/2403/5/11)

A GP complained about a Daily Mail article on Pradaxa. PMCPA assessed BI’s press release (not the article) and ruled it breached…

2011
CASE
AUTH/2436/9/11 Shire Pharmaceuticals

AUTH/2436/9/11: Genzyme v Shire β€” VPRIV website claims (misleading comparative efficacy and manufacturing risk statements)

Shire’s VPRIV website was ruled misleading for β€œat least as effective as” (non-inferiority data), β€œdoes not require gene manipulation”, and β€œminimising the…

2018
CASE
AUTH/3119/11/18 Pfizer ⭐ Case of the Week

AUTH/3119/11/18: Director v Pfizer β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3119/11/18 (Director v Pfizer) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2018
CASE
AUTH/3099/9/18 Allergan

AUTH/3099/9/18: Director v Allergan β€” late posting of clinical trial results on EUCTR

PMCPA took up a BMJ analysis of EUCTR reporting. Allergan was found in breach of Clause 9.1 for late EUCTR results posting…

2012
CASE
AUTH/2517/6/12 ProStrakan

AUTH/2517/6/12: Anonymous v ProStrakan – Adcal-D3 Caplet promotion and sales briefing (Clause 15.9 breach)

Anonymous complaint alleged misleading trial claims and a β€œswitch programme” for Adcal-D3 Caplet. Panel found no breach for promo materials or therapy…

2012
CASE
AUTH/2497/4/12 Vifor Pharma

AUTH/2497/4/12: Pharmacosmos v Vifor β€” competitor dosing information (Monofer) (No breach)

Pharmacosmos alleged Vifor reps misled HCPs that Monofer total dose infusion had a 1,000mg max. Panel found evidence insufficient on balance of…

2012
CASE
AUTH/2476/2/12 Allergan

AUTH/2476/2/12: Anonymous v Allergan (conduct of employees at IMCAS/Merz symposium) – No breach

Anonymous complaint alleged two Allergan employees were removed from a Merz symposium for photographing/recording despite warnings. Panel found insufficient evidence of poor…

2011
CASE
AUTH/2449/11/11 Boehringer Ingelheim ⭐ Case of the Week

Boehringer Ingelheim & Lilly: Trajenta β€œControl and care matter” leavepiece – no breach (AUTH/2449/11/11, AUTH/2450/11/11)

A GP alleged Trajenta β€œwith a difference” claims were misleading vs other DPP-4 inhibitors (dose adjustment, renal monitoring, food). Panel and Appeal…

2013
CASE
AUTH/2579/2/13 Bayer

Bayer: β€˜Mirena training workshop’ weblink found misleading (EvoInserter training expectation) β€” AUTH/2579/2/13

A GP said he was misled into attending what he thought was EvoInserter training for Mirena. PMCPA found the β€˜Mirena training workshop’…

2012
CASE
AUTH/2556/11/12 Janssen

Janssen: Sponsorship of ISU urology meeting in Belfast raised hospitality concerns (AUTH/2556/11/12)

Anonymous NHS HCPs complained about excessive hospitality at a 5-star Belfast urology meeting with golf and a gala dinner. Janssen was found…

2013
CASE
AUTH/2602/5/13 Chugai

AUTH/2602/5/13: Anonymous v Chugai Pharma UK – Provision of hospitality (No breach)

Anonymous complaint alleged Chugai staff bought rounds of drinks for health professionals in a hotel bar after a conference dinner. Chugai denied…

2012
CASE
Abbott Healthcare Products

Abbott breached ABPI Code after Hidrasec ads appeared on Facebook (public promotion of POM)

A GP complained that Hidrasec ads were visible on Facebook. The Panel ruled this effectively promoted a prescription-only medicine to the public…

2013
CASE
AUTH/2633/8/13 Leo Pharma ⭐ Case of the Week

Leo Pharma: Picato β€˜Dear Dr’ template letter pad alleged to bypass non-formulary status (AUTH/2633/8/13) – No breach

A pharmacist alleged Leo’s pre-printed β€˜Dear Dr’ forms for Picato were used to bypass local formulary status. PMCPA found the material didn’t…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training